Ces premiers résultats de la cohorte ECHO, soutenue par les US National Institutes of Health (NIH), confirment la relation entre le microbiome intestinal du nourrisson et les traits liés à l'autisme i ...

Cette nouvelle approche, développée par ces biologistes de l’Albert Einstein College of Medicine (Bronx, NY) pourrait améliorer l'efficacité des greffes de cellules souches, aujourd’hui couramment uti ...

Nouveau plaidoyer pour les nouveaux vaccins contre le virus respiratoire syncytial (VRS), dont l’impact, depuis leur introduction l'année dernière, est très surveillé. Cette nouvelle étude, menée par ...

Dans un contexte d'utilisation croissante de médicaments de perte de poids, la santé des muscles squelettiques ne doit pas être oubliée, rappelle cette équipe d’endocrinologues et de spécialistes du m ...

HOPO Therapeutics, Inc. announced today that it has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the ...

Per the agreement, Beckman Coulter will initially distribute BioPorto’s NGAL test in Europe followed by distribution in the United States pending US Food and Drug Administration (FDA) marketing ...

SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of ...

BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of intranasal vaccines, today announced that the company will present its significant progress in advancing ...

2024 ThinkEquity Conference Date: October 30, 2024 Location: New York, NY Format: Company Presentation Time: 10:30 a.m. ET BIO-Europe 2024 Date: November 5, 2024 Location: Stockholm, Sweden Format: ...

FREDERICK, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI” or the “Company”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination, ...

The CardiAMP HF Trial is assessing the safety and effectiveness of the CardiAMP ® Cell Therapy System for HFrEF, with the potential to reduce all cause death, future hospitalizations, enhance ...

Lim, MD, PhD, CEO of Medicovestor, Inc. “Our platform not only functionally enhances tumor antigen density but also enables multiple mechanisms for tumor cell destruction. The backbone antibodies ...